The Federal Government Just Broke Its Medical-Marijuana Promise

Ron Strider

Well-Known Member
Few if any industries are growing at a quicker and more consistent pace in the U.S. than marijuana. A report released earlier this year by Marijuana Business Daily entitled "Marijuana Business Factbook 2017" found that the U.S. legal-weed market is expected to grow by 45% in 2018, and an aggregate of 300% between 2016 and 2021. If these projections are accurate, we could be talking about a $17 billion market by 2021. With growth like this, it's no wonder why marijuana stocks have gone through the roof in recent years.

But at the same time, the federal government has hardly adjusted its stance on marijuana. The drug remains a Schedule I substance at the federal level, meaning it has no recognized medical benefits, and is deemed to be completely illegal, right alongside LSD and heroin.

This scheduling has also made life difficult for marijuana-based businesses. For example, most are unable to access basic banking services, ranging from a line of credit or loan to something as simple as a checking account. That's because banks answer to the Federal Deposit Insurance Corporation, a federally created entity. Since pot is illegal at the federal level, it's always possible that banks could face money-laundering charges or fines for providing financial services to pot businesses.

Marijuana companies also find no solace come tax time. U.S. tax code 280E disallows businesses that sell federally illegal substances from taking corporate income-tax deductions. The end result is that they're forced to pay tax on their gross profits instead of net profits, assuming they're even profitable in the first place.

The federal government broke its medical-marijuana promise

If there's been one small victory for pro-legalization enthusiasts at the federal level, it was the announcement from the Obama administration in 2016 that it'd be removing some of the red tape that keeps researchers from examining the medical benefits and risks of cannabis. In particular, the new policy on medical-cannabis research was designed to allow other universities, aside from the University of Mississippi, which has been the only authorized cannabis grower for the federal government since 1968, to grow medical cannabis. Ending the University of Mississippi's monopoly and introducing new supply was expected to be a boon to the research industry.

Or so everyone thought.

Attorney General Jeff Sessions, head of the Justice Department, and the U.S. Drug Enforcement Agency (DEA), have been butting heads for months over requests to expand medical-marijuana research (and supply in the process). Despite 25 proposals to grow medical cannabis on contract with the federal government, and a bipartisan letter requesting Sessions consider these proposals, the Justice Department has dug in its heels and thus far maintained a monopoly for the University of Mississippi.

And that's still not all.

As Forbes reports, the DEA has requested researchers grow 443,680 grams in 2018, or a tad over 978 pounds of cannabis, to conduct their research. This works out to a modest decline from the amount of cannabis produced for medical research in 2017. That's right, folks: Despite the federal government's announcement of an expansion of its medical-marijuana research program in 2016, it's broken that promise.

This makes the federal government's stalling a head-scratcher

Even if Sessions doesn't agree with marijuana's expansion, which he's made very clear through his speeches and actions, it's a complete head-scratcher that the federal government has stood pat on medical-cannabis research when a handful of clinical-stage drug developers have showed positive clinical benefits.

For example, GW Pharmaceuticals reported very encouraging data from its cannabidiol-based lead drug Epidiolex as a treatment for two rare types of childhood-onset epilepsy. Cannabidiol is the non-psychoactive component of cannabis. In two studies each for Dravet syndrome and Lennox-Gastaut syndrome, GW Pharmaceuticals' lead drug wound up significantly reducing the frequency of seizures in patients relative to the placebo. In fact, the reduction was three times greater in Dravet syndrome (39% to 13%) compared with the baseline.

Insys Therapeutics, an embattled drug developer that has two approved drugs on the market, has shown similarly positive results. One of those drugs, which was recently launched, is Syndros, an oral dronabinol solution designed to treat chemotherapy-induced nausea and vomiting, as well as anorexia associated with AIDS. This drug is essentially a synthetic form of tetrahydrocannabinol, the psychoactive component of cannabis known in shorthand as "THC."

While medical-cannabis trials haven't all been successful -- GW Pharmaceuticals' cancer pain studies involving Sativex in the U.S. failed miserably -- I would surmise they've delivered enough in the way of encouraging results to merit increased federal research.

Perhaps the bigger issue is that without this clearly defined benefit-versus-risk analysis from researchers, there's virtually no chance Congress will reschedule marijuana. As long as the red tape remains in place, researchers simply won't have the means to conduct the research needed to sway lawmakers. That's an ongoing concern for a burgeoning industry that's still illegal at the federal level.

Handful_of_Marijuana_-_Anne-Marie_Weber.jpg


News Moderator: Ron Strider 420 MAGAZINE ®
Full Article: The Federal Government Just Broke Its Medical-Marijuana Promise -- The Motley Fool
Author: Sean Williams
Contact: Contact Customer Service
Photo Credit: Anne-Marie Weber
Website: Fool.com: Stock Investing Advice | Stock Research
 
Insys Therapeutics, an embattled drug developer that has two approved drugs on the market, has shown similarly positive results. One of those drugs, which was recently launched, is Syndros, an oral dronabinol solution designed to treat chemotherapy-induced nausea and vomiting, as well as anorexia associated with AIDS. This drug is essentially a synthetic form of tetrahydrocannabinol, the psychoactive component of cannabis known in shorthand as "THC."

Insys Therapeutics, an embattled drug developer that has two approved drugs on the market
Say what now? An embattled drug developer? Insys Therapeutics? Another article posted on here titled Insys Fighting Cannabis Legalization - It Would Limit Commerical Success Of Its Drugs talks about them perfectly:

Insys Therapeutics Inc, gave $500,000 to Arizonans for Responsible Drug Policy, a prominent anti-marijuana legalization group, becoming the group's single largest donor,

Insys markets drugs for those undergoing chemotherapy treatments, including Subsys, a fentanyl-based painkiller. Fentanyl is a synthetic opioid painkiller that is 80 to 100 times more powerful than morphine and about 40 to 50 times more potent than 100% pure heroin.

The company is also developing Dronabinol, a synthetic cannabinoid - a blanket term referring to the active compounds in the marijuana plant - to reduce nausea and vomiting associated with chemotherapy. Dronabinol was approved by the FDA in July.

Though an Insys representative told The Arizona Republic that they oppose marijuana legalization because it "fails to protect" Arizona's children, a recent filing Insys made to the Securities and Exchange Commission (SEC) tells a different story.

From the filing:

"Legalization of marijuana or non-synthetic cannabinoids in the United States could significantly limit the commercial success of any dronabinol product candidate ... Literature has been published arguing the benefits of marijuana over dronabinol. Moreover, irrespective of its potential medical applications, there is some support in the United States for legalization of marijuana.

If marijuana or non-synthetic cannabinoids were legalized in the United States, the market for dronabinol product sales would likely be significantly reduced and our ability to generate revenue and our business prospects would be materially adversely affected."

By Insys's own admission, marijuana legalization in Arizona would likely "significantly" reduce the market for their synthetic drug, Dronabinol.

Insys produces a fentanyl-based opioid which is "80 to 100 times more powerful than morphine and about 40 to 50 times more potent than 100% pure heroin" and is greatly responsible for the current opioid epidemic that according to the CDC is claiming the lives of 91 Americans every day or more than 33,000 every year. If you or I killed just one person we'd get thrown in jail for 20 to life, but if you're a massive corporation you can mass murder tens of thousands of people every single year from an actually dangerous and addictive drug and not only avoid jail but also rake in obscene profit from killing almost a hundred people a day.

Insys also gave half a million dollars to Arizonans for Responsible Drug Policy, a group who oppose cannabis legalization. Although their public reason for opposing marijuana legalization was "because it "fails to protect" Arizona's children" (it's amazing how often 'think of the children' is used by those in power to prevent or push for certain laws), however their real reason for opposing the legalization of cannabis is because they have produced a synthetic cannabinoid called Dronabinol and if cannabis were legalized then "the market for dronabinol product sales would likely be significantly reduced and our [Insys] ability to generate revenue and our business prospects would be materially adversely affected." Insys paid half a million dollars to a group to oppose cannabis legalization not because cannabis is 'dangerous' or 'harms children' but because it would significantly reduce the profits that Insys could generate from their synthetic cannabinoid. That's right, people allowed to access the plant to smoke or eat is bad but a synthetic fake copy of one or more substances from that plant in pill form is perfectly fine because the pill will generate billions of dollars in profit for Big Harma, the industry of death, whereas if cannabis were legal people could grow it themselves or buy it from a local store and could get their healing from a miracle plant instead of a pharmaceutical pill.
 
Insys Therapeutics, an embattled drug developer that has two approved drugs on the market
Say what now? An embattled drug developer? Insys Therapeutics? Another article posted on here titled Insys Fighting Cannabis Legalization - It Would Limit Commerical Success Of Its Drugs talks about them perfectly:



Insys produces a fentanyl-based opioid which is "80 to 100 times more powerful than morphine and about 40 to 50 times more potent than 100% pure heroin" and is greatly responsible for the current opioid epidemic that according to the CDC is claiming the lives of 91 Americans every day or more than 33,000 every year. If you or I killed just one person we'd get thrown in jail for 20 to life, but if you're a massive corporation you can mass murder tens of thousands of people every single year from an actually dangerous and addictive drug and not only avoid jail but also rake in obscene profit from killing almost a hundred people a day.

Insys also gave half a million dollars to Arizonans for Responsible Drug Policy, a group who oppose cannabis legalization. Although their public reason for opposing marijuana legalization was "because it "fails to protect" Arizona's children" (it's amazing how often 'think of the children' is used by those in power to prevent or push for certain laws), however their real reason for opposing the legalization of cannabis is because they have produced a synthetic cannabinoid called Dronabinol and if cannabis were legalized then "the market for dronabinol product sales would likely be significantly reduced and our [Insys] ability to generate revenue and our business prospects would be materially adversely affected." Insys paid half a million dollars to a group to oppose cannabis legalization not because cannabis is 'dangerous' or 'harms children' but because it would significantly reduce the profits that Insys could generate from their synthetic cannabinoid. That's right, people allowed to access the plant to smoke or eat is bad but a synthetic fake copy of one or more substances from that plant in pill form is perfectly fine because the pill will generate billions of dollars in profit for Big Harma, the industry of death, whereas if cannabis were legal people could grow it themselves or buy it from a local store and could get their healing from a miracle plant instead of a pharmaceutical pill.
It's always been a matter of which liar to vote for.....the country makes no difference. Money talks........BS!
 
Back
Top Bottom